Allena Pharmaceuticals

OverviewSuggest Edit

Allena Pharmaceuticals is a company that develops and commercializes non-systemic protein therapeutics to treat metabolic and orphan diseases. It is focused on treating complex metabolic conditions that can lead to significant and costly health complications. The company aims to reduce the burden of toxic metabolites such as oxalate and uric acid, which can build up and lead to complications such as hyperoxaluria and kidney stones (nephrolithiasis) in the case of oxalate, or hyperuricemia and gout in the case of uric acid.

TypePublic
Founded2011
HQNewton, MA, US
Websiteallenapharma.com

Latest Updates

Employees (est.) (Mar 2020)34(-30%)
Share Price (Nov 2021)$0.9(-2%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Allena Pharmaceuticals

Hugh Wight

Hugh Wight

Vice President of Technical Operations
Louis Brenner

Louis Brenner

President and Chief Executive Office
Edward Wholihan

Edward Wholihan

CFO
Annamaria Kausz

Annamaria Kausz

Chief Medical Officer
Geoffrey Swire

Geoffrey Swire

VP, Program & Alliance Management
Stephen Yu

Stephen Yu

VP, Quality Assurance
Show more

Allena Pharmaceuticals Office Locations

Allena Pharmaceuticals has offices in Newton and Sudbury
Newton, MA, US (HQ)
1 Executive Park Dr # 202
Sudbury, MA, US
142B North Road
Show all (2)

Allena Pharmaceuticals Financials and Metrics

Allena Pharmaceuticals Revenue

USD

Net income (Q1, 2021)

(11.6m)

EBIT (Q1, 2021)

(11.4m)

Market capitalization (12-Nov-2021)

69.8m

Closing stock price (12-Nov-2021)

0.9

Cash (31-Mar-2021)

36.3m

EV

47.9m
Allena Pharmaceuticals's current market capitalization is $69.8 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

General and administrative expense

5.4m9.2m9.7m11.6m

R&D expense

15.5m26.4m37.2m20.4m

Operating expense total

21.0m35.6m46.9m32.0m

Interest expense

700.0k55.0k
Quarterly
USDQ3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

General and administrative expense

1.4m2.0m2.3m2.4m2.4m2.7m2.5m2.9m2.8m3.6m

R&D expense

2.9m5.9m5.9m7.3m9.1m8.6m10.8m4.6m3.8m7.9m

Operating expense total

4.4m8.0m8.1m9.7m11.6m11.3m13.3m7.5m6.6m11.4m

EBIT

(4.4m)(8.0m)(8.1m)(9.7m)(11.6m)(11.3m)(13.3m)(7.5m)(6.6m)(11.4m)
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

94.5m61.6m30.0m35.0m

Prepaid Expenses

1.5m2.8m3.0m2.2m

Current Assets

96.0m64.5m33.0m37.2m

PP&E

127.0k514.0k401.0k881.0k
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(21.6m)(35.6m)(47.3m)(32.8m)

Depreciation and Amortization

73.0k78.0k163.0k166.0k

Accounts Payable

199.0k441.0k972.0k(544.0k)

Cash From Operating Activities

(21.1m)(31.8m)(43.6m)(28.2m)
Quarterly
USDQ3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(15.0m)(7.9m)(16.5m)(26.0m)(11.4m)(22.7m)(36.0m)(7.6m)(14.6m)(11.6m)

Depreciation and Amortization

53.0k19.0k27.0k44.0k40.0k79.0k121.0k41.0k83.0k65.0k

Accounts Payable

150.0k529.0k(726.0k)(1.0k)534.0k216.0k1.5m(1.3m)(2.5m)468.0k

Cash From Operating Activities

(14.2m)(6.9m)(14.9m)(23.1m)(9.8m)(22.6m)(31.7m)(8.6m)(15.3m)(10.0m)
USDQ3, 2017

Financial Leverage

-0.5 x
Show all financial metrics

Allena Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Allena Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Allena Pharmaceuticals Online and Social Media Presence

Embed Graph

Allena Pharmaceuticals News and Updates

Thinking about buying stock in PROG Holdings, Criteo SA, Pacific Biosciences, Allena Pharmaceuticals, or Intercept Pharmaceuticals?

NEW YORK, Nov. 3, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRG, CRTO, PACB, ALNA, and ICPT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Allena Pharmaceuticals Commences Dosing of Gout Patients in Second Phase 2a Trial of ALLN-346

- Fourteen-day study focused on high unmet need in patients with gout and chronic kidney disease -

Allena Pharmaceuticals to Participate in H.C. Wainwright’s 23rd Annual Global Investment Conference

NEWTON, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases…

Allena Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Corporate Progress

NEWTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-…

Allena Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference

NEWTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today an…
Show more

Allena Pharmaceuticals Blogs

Allena Pharmaceuticals to Participate in the Stifel 2021 Virtual Healthcare Conference

NEWTON, Mass. , Nov. 15, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals , Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic

Allena Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Corporate Progress

Allena Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Corporate Progress Content Import Wed, 11/10/2021 - 16:11 Allena Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Corporate Progress November 10, 2021 at 4:05 PM EST …

Allena Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial of ALLN-346, in Development for the Treatment of Hyperuricemia in Patients with Gout and Advanced Chronic Kidney Disease

Allena Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial of ALLN-346, in Development for the Treatment of Hyperuricemia in Patients with Gout and Advanced Chronic Kidney Disease Content Import Tue, 09/08/2020 - 08:02 Allena Pharmaceuticals Doses First Subject in Phase 1 Clinica…

Allena Pharmaceuticals to Present Virtually at Upcoming Investor Conferences in September

Allena Pharmaceuticals to Present Virtually at Upcoming Investor Conferences in September Content Import Thu, 09/03/2020 - 08:01 Allena Pharmaceuticals to Present Virtually at Upcoming Investor Conferences in September September 3, 2020 This release is a back…

Allena Pharmaceuticals to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

NEWTON, Mass. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today

Allena Pharmaceuticals Announces $5.0 Million Bought Deal Offering

Allena Pharmaceuticals Announces $5.0 Million Bought Deal Offering Content Import Mon, 07/27/2020 - 16:53 Allena Pharmaceuticals Announces $5.0 Million Bought Deal Offering July 27, 2020 This release is a backfill from a News Wire General …
Show more

Allena Pharmaceuticals Frequently Asked Questions

  • When was Allena Pharmaceuticals founded?

    Allena Pharmaceuticals was founded in 2011.

  • Who are Allena Pharmaceuticals key executives?

    Allena Pharmaceuticals's key executives are Hugh Wight, Louis Brenner and Edward Wholihan.

  • How many employees does Allena Pharmaceuticals have?

    Allena Pharmaceuticals has 34 employees.

  • Who are Allena Pharmaceuticals competitors?

    Competitors of Allena Pharmaceuticals include Biogen, CSL Behring and Evotec.

  • Where is Allena Pharmaceuticals headquarters?

    Allena Pharmaceuticals headquarters is located at 1 Executive Park Dr # 202, Newton.

  • Where are Allena Pharmaceuticals offices?

    Allena Pharmaceuticals has offices in Newton and Sudbury.

  • How many offices does Allena Pharmaceuticals have?

    Allena Pharmaceuticals has 2 offices.